bevacizumab-vikg

Lytenava, Outlook Therapeutics, Avastin, Roche, wet AMD, bevacizumab-vikg, Complete response letter

Outlook’s eye drug Lytenava fails to win FDA approval, despite positive trial

Anika Sharma

Outlook Therapeutics has been working on a reformulated version of Roche’s cancer drug Avastin for the treatment of certain eye ...